About GeneDx
GeneDx is a company based in Gaithersburg (United States) founded in 2000 was acquired by Sema4 in January 2022. The company has 1,000 employees as of December 31, 2024. GeneDx has completed 1 acquisition, including Fabric Genomics. GeneDx offers products and services including XomeDx, GenomeSeqDx, and GenomeXpress. GeneDx operates in a competitive market with competitors including Natera, ArcherDX, Variantyx, ImaginAb and Lantern Pharma, among others.
- Headquarter Gaithersburg, United States
- Employees 1000 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Genedx Holdings Corp.
-
Annual Revenue
$305.45 M (USD)50.79as on Dec 31, 2024
-
Net Profit
-$52.29 M (USD)70.25as on Dec 31, 2024
-
EBITDA
$492 K (USD)0as on Dec 31, 2024
-
Latest Funding Round
Not available
-
Investors
Bioreference
& 1 more
-
Employee Count
1000
as on Dec 31, 2024
- Investments & Acquisitions
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of GeneDx
GeneDx is a publicly listed company on the NASDAQ with ticker symbol WGS in USA, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of GeneDx
GeneDx offers a comprehensive portfolio of products and services, including XomeDx, GenomeSeqDx, and GenomeXpress.
Test for diagnosing genetic disorders with higher yield than alternatives.
Comprehensive test including mitochondrial analysis for rare diseases.
Accelerates diagnosis for infants in intensive care units.
People of GeneDx
Unlock access to complete
Unlock access to complete
Leadership Team
20 people
Software Development Team
8 people
Finance and Accounting
7 people
Sales and Marketing
6 people
Operations Team
5 people
Board Team
5 people
Human Resources and Administration
4 people
Data Analysis and Operations Team
4 people
Unlock access to complete
Funding Insights of GeneDx
Detailed funding history for GeneDx
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in GeneDx
GeneDx has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Bioreference and GeneDx.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Pathology laboratory services are operated through a nationwide chain.
|
Locked | Locked | Locked | |
|
Genome-based diagnostic solutions for reproductive health and oncology are provided.
|
Locked | Locked | Locked |
Investor details for GeneDx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by GeneDx
GeneDx has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Fabric Genomics.
Investment portfolio details for GeneDx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
AI-based disease diagnosis and genomic analysis tool for providers
|
Locked | Locked | 0 | Locked |
Complete acquisition details for GeneDx
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - GeneDx
Detailed financials for GeneDx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Genedx Comparisons
Peer comparison for GeneDx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of GeneDx
GeneDx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Natera, ArcherDX, Variantyx, ImaginAb and Lantern Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Genomics data analysis platform for healthcare diagnostics is offered.
|
|
| Locked | Locked | Locked |
ImaginAb is focused on developing advanced immuno-oncology imaging technologies.
|
|
| Locked | Locked | Locked |
Drug and companion diagnostics for multi-drug resistant cancers are developed.
|
|
| Locked | Locked | Locked |
Developer of technologies for the analysis of rare and single cells in the blood
|
Detailed competitors of GeneDx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Genedx
Complete news archive for GeneDx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GeneDx
GeneDx was founded in 2000.
GeneDx is headquartered in Gaithersburg, United States. It is registered at Gaithersburg, Maryland, United States.
As of Dec 31, 2024, the latest employee count at GeneDx is 1,000.
Annual revenue of GeneDx is $305.45M as on Dec 31, 2024.
Provider of genetic testing for inherited disorders. The company has CLIA certified labs that carry out genetic tests covering a range of medical specialties including cardiology, endocrinology, metabolic disorders, developmental disorders, hematology, immunology, oncology (hereditary cancer syndromes), among others. The company offers whole-exome sequencing with or without mitochondrial DNA sequencing, with or without reporting of incidental findings in the clinical reports.
GeneDx's top competitors include Natera, ImaginAb and Lantern Pharma.
GeneDx offers XomeDx, GenomeSeqDx, and GenomeXpress.
Yes, GeneDx is publicly traded on NASDAQ under the ticker symbol WGS.
GeneDx has made 1 acquisition, including Fabric Genomics.
GeneDx has 2 investors. Key investors include Bioreference, and GeneDx.
The ticker symbol of GeneDx is WGS on NASDAQ.